June 21, 2022
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treating Fields… Read More
learn more
June 3, 2022
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to… Read More
learn more
May 26, 2022
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of… Read More
learn more
April 28, 2022
Novocure Reports First Quarter 2022 Financial Results
Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend… Read More
learn more
April 19, 2022
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
Governor Sununu and Novocure leadership delivered keynote remarks, celebrating the construction of Novocure’s new flagship facility in Portsmouth, NH ST. HELIER, Jersey–(BUSINESS WIRE)–Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown… Read More
learn more
April 8, 2022
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentations spans… Read More
learn more
April 1, 2022
Novocure to Report First Quarter 2022 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended… Read More
learn more
March 24, 2022
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the… Read More
learn more
March 23, 2022
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together… Read More
learn more
February 28, 2022
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
Professor Palti is the inventor of Tumor Treating Fields, electric fields that disrupt cancer cell division The Israel Prize is regarded as the State of Israel’s highest cultural honor ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s Founder and Chief Technology Officer, has… Read More
learn more